Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B
Open Access
- 31 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0262198
Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture high-risk CRC patients who are most likely to recur. We aimed to improve high-risk classification by identifying biological pathways associated with outcome in adjuvant stage II/III CRC. Methods and findings: We included 1062 patients with stage III or high-risk stage II colon carcinoma from the prospective three-arm randomized phase 3 AVANT trial, and performed expression profiling to identify a prognostic signature. Data from validation cohort GSE39582, The Cancer Genome Atlas, and cell lines were used to further validate the prognostic biology. Our retrospective analysis of the adjuvant AVANT trial uncovered a prognostic signature capturing three biological functions—stromal, proliferative and immune—that outperformed the Consensus Molecular Subtypes (CMS) and recurrence prediction signatures like Oncotype Dx in an independent cohort. Importantly, within the immune component, high granzyme B (GZMB) expression had a significant prognostic impact while other individual T-effector genes were less or not prognostic. In addition, we found GZMB to be endogenously expressed in CMS2 tumor cells and to be prognostic in a T cell independent fashion. A limitation of our study is that these results, although robust and derived from a large dataset, still need to be clinically validated in a prospective study. Conclusions: This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in biomarker defined subpopulations of resectable high-risk CRC. Our results also shed light on an alternative GZMB source with context-specific implications on the disease’s unique biology.Keywords
Funding Information
- Genentech Inc., a member of the Roche group
- Dutch Cancer Society (KWF Kankerbestrijding (2013-5885)
This publication has 56 references indexed in Scilit:
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancerThe Journal of Pathology, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLOS Medicine, 2013
- A colorectal cancer classification system that associates cellular phenotype and responses to therapyNature Medicine, 2013
- Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesBMC Medical Genomics, 2012
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis InitiationCancer Cell, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer AssayBMC Cancer, 2010
- Distinct Transcriptional Profiles in Ex Vivo CD4+and CD8+T Cells Are Established Early in Human Immunodeficiency Virus Type 1 Infection and Are Characterized by a Chronic Interferon Response as Well as Extensive Transcriptional Changes in CD8+T CellsJournal of Virology, 2007
- Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cellsJournal of Leukocyte Biology, 2006
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004